Abstract
We report the emergence of an influenza virus A/H3N2-E119V neuraminidase variant from an elderly patient with renal dysfunction who received a suboptimal dose of oseltamivir prophylaxis. In neuraminidase inhibition assays, the E119V variant showed a 413-fold increase in the 50% inhibitory oseltamivir concentration and grew at titers comparable to those of the wild type in vitro.
MeSH terms
-
Aged, 80 and over
-
Antiviral Agents / therapeutic use*
-
Chemoprevention / methods*
-
Drug Resistance, Viral*
-
Female
-
Humans
-
Influenza A Virus, H3N2 Subtype / drug effects
-
Influenza A Virus, H3N2 Subtype / growth & development
-
Influenza A Virus, H3N2 Subtype / isolation & purification*
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology*
-
Inhibitory Concentration 50
-
Microbial Sensitivity Tests
-
Molecular Sequence Data
-
Mutation, Missense
-
Neuraminidase / genetics
-
Oseltamivir / therapeutic use*
-
RNA, Viral / genetics
-
Sequence Analysis, DNA
-
Viral Load
-
Viral Proteins / genetics
Substances
-
Antiviral Agents
-
RNA, Viral
-
Viral Proteins
-
Oseltamivir
-
NA protein, influenza A virus
-
Neuraminidase
Associated data
-
GENBANK/KF685746
-
GENBANK/KF685747